Clinical Trials
34 trialsCaDAnCe-101
BeOne Medicines
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
MK-1026-003
Merck Sharp & Dohme LLC
KEYNOTE145
Acerta Pharma BV
BAF_FRontier-1
Eli Lilly and Company
CAN3001
Janssen Research & Development, LLC
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta, Inc.
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Acerta Pharma BV
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
CLOVER-WaM
Cellectar Biosciences, Inc.
ZUMA-25
Gilead Sciences
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
BeOne Medicines
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger, Inc.
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
RUBIN
iOMEDICO AG
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Eli Lilly and Company
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
BeOne Medicines
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Carna Biosciences, Inc.
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
BeOne Medicines
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
ARIADNE
iOMEDICO AG
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
MAPLE-1
Ascentage Pharma Group Inc.